Phase 3 Study of KHK7580

Inclusion Criteria: * Personally submitted written voluntary informed consent to participate in the study * Stable chronic renal disease treated with hemodialysis 3 times weekly for at least 12 weeks before screening * Intact PTH level of \> 240 pg/ml at screening (except subjects receiving cinacalcet hydrochloride at screening) Exclusion Criteria: * Change in dose or dosing regimen of cinacalcet hydrochloride or activated vitamin D drug or its derivative, phosphate binder, or calcium preparation within 2 weeks before screening; or start of treatment with such drugs within 2 weeks before screening; * Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening; * Severe heart disease; * Severe hepatic dysfunction; * Uncontrolled hypertension and/or diabetes; * Treatment with an investigational product (drug or medical device) in a clinical study or any study equivalent to clinical study within 12 weeks before screening; * Primary hyperparathyroidism; * Other conditions unfit for participation in this study at the discretion of the investigator or subinvestigator.